First preclinical SPECT/CT imaging and biodistribution of [¹⁶⁵Er]ErCl₃ and [¹⁶⁵Er]Er-PSMA-617.

ABSTRACT:

Background

¹⁶⁵Er (t_1/2 = 10.4 h, E_x-ray = 47.1 keV (59.4%) and 54.3 keV (14.3%)) is a promising radionuclide suitable for targeted Auger electron therapy of cancer. ¹⁶⁵Er can be produced at a relatively low cost, high yield, and high purity using small medical cyclotrons. As a late lanthanide, ¹⁶⁵Er is easy to label and can be used as a surrogate for other lanthanides or Ac in proof-of-concept studies. In this report, we explore the radiochemistry, in vitro, and in vivo behavior of [¹⁶⁵Er]ErCl₃ and [¹⁶⁵Er]Er-PSMA-617 to showcase the application of this radionuclide. Particularly, we report the first phantom and preclinical SPECT imaging of this radionuclide leveraging its characteristic X-ray ph

SUBMITTER: Saeedi Saghez B 

PROVIDER: S-EPMC11655927 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature